Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx-Reference-Cited by-同舟云学术

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

Published:2001-06-01 Issue:6 Volume:47 Page:519-524
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:
Short-container-title:Cancer Chemotherapy and Pharmacology

Author:

Bier Henning,Hoffmann Thomas,Hauser Ulrich,Wink Michael,Öchler Martin,Kovar Andreas,Müser Matthias,Knecht Reinald

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s002800000270.pdf

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CCL27 Signaling in the Tumor Microenvironment;Advances in Experimental Medicine and Biology;2021

2. Generation of humanized single-chain fragment variable immunotherapeutic against EGFR variant III using baculovirus expression system and in vitro validation;International Journal of Biological Macromolecules;2019-03

3. Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck;Head and Neck Cancer;2016

4. Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma;Journal of Oral and Maxillofacial Surgery;2015-12

5. Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck;The Oncologist;2015-10-07